Ember LifeSciences secures strategic investments to expand cold chain tech for medicine delivery

Ember LifeSciences announced new strategic investments from Amgen Ventures and TDF Ventures to accelerate the growth of its cold chain logistics platform. The company recently launched the Ember Cube 2, an award-winning reusable shipping solution that enhances temperature control and real-time monitoring for pharmaceutical distribution. These investments will help Ember scale globally amid rising demand for precise temperature-controlled medicine transport, addressing billions in losses from temperature excursions. Ember has raised $27 million in Series A funding to date and counts major pharma distributors like CVS Health among its customers.